Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Gynecologic 2

Conditions

Neoplasms 5Triple Negative Breast Neoplasms 4Breast Neoplasms 4Recurrence 2Ovarian Neoplasms 2Hypersensitivity 2Brain Neoplasms 2Squamous Cell Lung Cancer 1Solid Tumors 1Neoplasm Metastasis 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neoplasms × iniparib × Clear all
NCT00422682 2016-06-10

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
136 enrolled
Tumor-Agnostic

Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
41 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Sanofi

Phase 2 Completed
43 enrolled
Gynecologic

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT00298675 2012-08-02

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡